Media coverage about Varian Medical Systems (NYSE:VAR) has trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Varian Medical Systems earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 45.2337349624719 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern’s scoring:
- Global Healthcare Robotics Market Research Report,Global Medical Robotics System Industry Analysis (centraljersey.com)
- $693.86 Million in Sales Expected for Varian Medical Systems (VAR) This Quarter (americanbankingnews.com)
- Varian Medical Systems Inc. – Receive News & Ratings Daily (thecasualsmart.com)
- Citi Remains Bullish on Varian Medical Systems (VAR) Following 2Q Preview (streetinsider.com)
- Zacks: Analysts Anticipate Varian Medical Systems (VAR) Will Announce Earnings of $1.03 Per Share (americanbankingnews.com)
Several research firms have recently issued reports on VAR. Citigroup raised their target price on shares of Varian Medical Systems from $128.00 to $132.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. BTIG Research restated a “hold” rating on shares of Varian Medical Systems in a report on Sunday, January 28th. Barrington Research upgraded shares of Varian Medical Systems from a “market perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a report on Thursday, January 25th. JPMorgan Chase lifted their price objective on shares of Varian Medical Systems from $88.00 to $105.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Finally, Goldman Sachs lowered shares of Varian Medical Systems from a “neutral” rating to a “sell” rating and set a $98.00 price objective for the company. in a report on Thursday, January 25th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Varian Medical Systems has a consensus rating of “Hold” and a consensus price target of $111.80.
Varian Medical Systems (NYSE:VAR) last announced its quarterly earnings data on Wednesday, January 24th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.06. Varian Medical Systems had a net margin of 4.27% and a return on equity of 27.13%. The company had revenue of $678.50 million during the quarter, compared to analyst estimates of $633.96 million. During the same quarter last year, the business posted $1.09 EPS. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis. equities analysts predict that Varian Medical Systems will post 4.31 EPS for the current year.
In other news, Director Susan L. Bostrom sold 1,952 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $120.60, for a total value of $235,411.20. Following the completion of the sale, the director now owns 3,809 shares in the company, valued at approximately $459,365.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP John W. Kuo sold 863 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $108.43, for a total transaction of $93,575.09. Following the completion of the sale, the senior vice president now owns 28,224 shares of the company’s stock, valued at approximately $3,060,328.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,187 shares of company stock valued at $9,987,401. Company insiders own 0.78% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Varian Medical Systems (VAR) Stock Price” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://stocknewstimes.com/2018/04/16/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-varian-medical-systems-var-stock-price-2.html.
About Varian Medical Systems
Varian Medical Systems, Inc designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through two segments, Oncology Systems and Varian Particle Therapy. The Oncology Systems segment provides hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy.
Receive News & Ratings for Varian Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varian Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.